An autocrine Vitamin D-driven Th1 shutdown program can be exploited for COVID-19
R. McGregor, D. Chauss, T. Freiwald, B. Yan, L. Wang, E. Nova-Lamperti, Z. Zhang, H. Teague, E. West, J. Bibby, A. Kelly, A. Malik, A. Freeman, D. Schwartz, D. Portilla, , B. Afzali
This study identifies a Vitamin D-driven mechanism that suppresses excessive Th1 responses in COVID-19, suggesting potential therapeutic use of Vitamin D analogs.
bioRxiv · Jul 18, 2020 · PreprintImmunology